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Background: When assessing patients with exacerbation of asthma or COPD, it may be useful 
to know the drop in forced expiratory volume in 1 second (FEV
1
) compared with stable state, 
in particular when considering treatment with oral corticosteroids. The objective of the study 
was to identify indicators of drop in FEV
1
 during exacerbations.
Methods: In this prospective multicenter study from primary care, patients diagnosed with 
asthma or COPD were examined at stable state and during exacerbations the following year. 
Symptoms, chest findings, and pulse oximetry were recorded, and spirometry was performed. 
A fixed drop in FEV
1
 (10% and $200 mL) and percentage change in FEV
1
 were outcomes 
when possible indicators were evaluated.
Results: Three hundred and eighty patients attended baseline examination, and 88 with a 
subsequent exacerbation were included in the analysis. Thirty (34%) had a significant drop 
in FEV
1
 (10% and 200 mL). Increased wheezing was the only symptom associated with this 
drop with a likelihood ratio of 6.4 (95% confidence interval, 1.9–21.7). Crackles and any new 
ausculta tion finding were also associated with a significant drop in FEV
1
, as was a $2% drop in 
oxygen saturation (SpO
2
) to 92% in the subgroup  diagnosed with COPD. Very bothersome 
wheezing and severe decrease in SpO
2
 were also very strong predictors of change in FEV
1
 in 
linear regression adjusted for age, gender, and baseline FEV
1
% predicted.
Conclusion: Increased wheezing, as experienced by the patient, and a decreased SpO
2
 value 
strongly indicated a drop in lung function during asthma and COPD exacerbations and should 
probably be taken into account when treatment with oral corticosteroids is considered.
Keywords: bronchial obstruction, systemic corticosteroids, diagnostic tests, primary care
Background
Patients with COPD or asthma frequently experience exacerbations of their ill-
ness. Studies from Norway and the UK have shown that each year ~50% of COPD 
patients experience an exacerbation that leads to a visit to a general practitioner 
(GP), in-hospital treatment, or self-administered treatment with antibiotics or sys-
temic corticosteroids.1,2 In a study from the United States, ~25% of asthma patients 
reported to use a short course with oral corticosteroids during a period of 3 months.3 
Treatment with systemic corticosteroids is recommended in both severe COPD 
exacerbations4,5 and asthma attacks.6,7 Such medication counteracts the inflamma-
tory response in the bronchial tree, and by doing so, alleviates the accompanying 
bronchial obstruction. In asthma attacks, there is firm evidence for a favorable effect 
of systemic corticosteroids,6 for COPD exacerbations the evidence refers mainly to 
clinical trials in hospitalized patients.4 In COPD guidelines, the criteria for starting 
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such treatment are not clear cut, but it is often recommended 
when symptoms are not relieved after stepping up treat-
ment with inhaled bronchodilators.8 Benefit from systemic 
corticosteroid treatment has to be weighed against adverse 
effects, such as increased fragility of the bones and increased 
blood levels of glucose.4
Improvement in lung function has been a main 
outcome measure in studies on the effects of systemic 
corticosteroids.9,10 This implies that the acute deteriora-
tion of lung function associated with the exacerbation is 
a main target for the systemic corticosteroids. It would, 
therefore, probably be useful, when deciding on prescrib-
ing systemic corticosteroids, to know whether the patient 
actually suffers from increased bronchial obstruction and 
if so, to which degree? However, doing spirometry in the 
acute phase of a COPD exacerbation is not recommended 
in the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) guidelines,5 and it might not be convenient 
in all cases with asthma attacks. Other sources of infor-
mation that could reflect increased bronchial obstruction 
could be the symptoms of the patient, as well as chest 
findings and assessment of oxygen saturation (SpO
2
) by 
pulse oximetry. The aim of this study was to describe how 
these clinical findings are associated with a decrease in 
lung function during exacerbations. We also wanted to find 
out whether the strength of these associations would be 




This observational prospective study was carried out in seven 
general practice offices in the north and south of Norway. 
Patients aged 40 years or older registered in the electronic 
medical record with a diagnosis of asthma or COPD (or 
both) in the previous 5 years were identified, and a random 
sample of 1,111 patients was invited to participate. Of the 380 
patients who met for baseline registration between April 2009 
and March 2010, 376 were considered to be in a stable phase 
of their disease and were included in the study. Out of those, 
210 were diagnosed with asthma by their GPs, 74 with COPD, 
and 92 with both asthma and COPD.11 They were all asked to 
visit their GP within 2–3 days if they experienced exacerba-
tions of their lung disease the following 12 months.
All participants gave written consent, and the study was 
approved by the Regional Committee for Medical and Health 
Research Ethics in North Norway.
examinations at baseline
Respiratory symptoms the previous week and relevant quality 
of life items were examined using the Norwegian translation 
of the Clinical COPD Questionnaire (CCQ).12 In the CCQ, 
the symptoms “short of breath at rest”, “short of breath doing 
physical activities”, coughing, and production of phlegm were 
classified into scores from 0 (never) to 6 (almost all the time), 
and a mean score of respiratory symptoms was calculated. The 
CCQ also contains questions on depression and concern about 
the disease getting worse with the same score system and four 
questions on activity limitation due to the illness, also with a 
score system from 0 (not limited at all) to 6 (totally limited). 
A total CCQ score as the mean of all 10 items was also calcu-
lated. Smoking habit and hospitalizations due to the lung disease 
the previous year were reported on a separate questionnaire. 
On a pop-up questionnaire in the electronic medical record the 
examining GP recorded comorbidities and treatment given, 
including antibiotics and systemic corticosteroids for exacer-
bations the previous year. Exacerbation of asthma or COPD 
the year before baseline was defined as exacerbations that 
were treated with antibiotics and/or systemic corticosteroids 
or ended with hospitalization, a definition previously used for 
COPD exacerbations.1 The GPs also reported the presence of 
wheezes, crackles, diminished breath sounds, and prolonged 
expiration after auscultation of the lungs. The examinations at 
baseline were shared between 20 GPs.
C-reactive protein (CRP) was analyzed using near 
patient tests: Afinion AS100 Analyzer, Orion Quickread 
CRP, or ABX Micros CRP, which all could display values 
down to 8 mg/L. SpO
2
 was measured by a digital handheld 
pulse oximeter, Onyx II model 0550 (Nonin Medical, Inc., 
Plymouth, MN, USA). The highest value of the three mea-
surements was recorded.
Spirometry was carried out after the pulse oximetry, 
following the European Respiratory Society/American 
Thoracic Society guidelines.13 Spirare SPS310 spirometers 
(Diagnostica AS, Oslo, Norway) were used. The patients 
were seated, and nose clip was not used. Post-bronchodilator 
spirometry was carried out 20 minutes after inhalation of 
0.4 mg salbutamol. The post-bronchodilator forced expira-
tory volume in 1 second (FEV
1
) and forced vital capacity 
(FVC) were used in the analyses. Norwegian reference values 
for spirometry were applied.14
examinations at exacerbations
The participants filled in the CCQ, this time concerning 
the previous 24 hours. Respiratory symptoms the previous 
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24 hours were also reported by the GPs based on history 
taking on a pop-up questionnaire and shortness of breath, 
coughing, phlegm production, and wheezing were classi-
fied into three grades: 1) not present or as normal, 2) more 
bothersome than normal, and 3) very bothersome. The GPs 
also recorded whether the sputum was yellowish or green. 
Chest findings, the CRP value, and pulse oximetry were 
recorded as done at baseline. Lung function testing was also 
carried out with the same procedure, but post-bronchodilator 
spirometry was not carried out.
statistical analysis
A significant drop in FEV
1
was defined as a drop of $10% 
from baseline15 and of at least 200 mL. How such a drop 
in FEV
1
 was associated with baseline characteristics and 
symptoms, signs and test results at exacerbation was ana-
lyzed by chi-square test, Fischer’s exact test (dichotomous 
variables), and Mann–Whitney test (the CCQ variables). 
The threshold used for raised CRP value was $20 mg/L. 
Two thresholds were used for SpO
2
, 92% and 95%. 
Changes from baseline were found by subtracting baseline 
values from the values at exacerbation. Significant increase 
in CRP was defined as an increase of at least 10 mg/L to 
a value of $20 mg/L. Significant decreases in SpO
2
 were 
defined as a reduction of at least 2% to 95% and 92%, 
respectively. Likelihood ratios were calculated for findings 
significantly associated with the fixed drop in FEV
1
 using 
online software (M.K. Anders Consulting). Associations with 
percentage change in FEV
1
 from baseline were analyzed by 
linear regression making it possible to have the degree of 
change as outcome. IBM SPSS Statistics software version 
22 was used.
Results
During the 1-year follow-up period, 109 patients visited their 
GP due to one or more exacerbations. For patients who visited 
the GP with several exacerbations, the first exacerbation was, 
as a rule, included in the analysis. However, 21 patients were 
excluded due to incomplete data from the exacerbations, in 
most cases because spirometry was not done. Seventeen GPs 
took part in the examinations of the 88 included patients at 
baseline, whereas 34 GPs shared the examinations during 
the exacerbations, and 41 patients (47%) were examined 
by the same GP both times. The mean age of the patients 
at baseline was 63 years, and 66% were female. A COPD 
diagnosis (or both asthma and COPD) had been given to 48 
(55%) patients at baseline, and patients with a COPD diag-
nosis had significantly more frequent history of exacerbation 
the previous year. They were also different from the patients 
in the asthma group in other ways (Table 1).
The distribution of FEV
1
 at baseline and at exacerbation 
is shown in Figure 1, with predicted mean values of 76.1% 
and 70.8%, respectively. Among the asthma patients, the cor-
responding FEV
1
% predicted values were 87.5 and 83.0 and 
Table 1 Baseline characteristics of 88 adult patients with asthma or COPD
Patient characteristics All, n=88 
n (%)
Diagnosed with asthma 
only, n=40, n (%)
Diagnosed with COPD or both 
asthma and COPD, n=48, n (%)
P-value
age $65 years 43 (49) 16 (40) 27 (56) 0.1
Male gender 34 (39) 16 (40) 18 (38) 0.8
Current smoker 27 (31) 9 (23) 18 (38) 0.1
Comorbidity
Coronary heart disease 15 (17) 4 (10) 11 (23) 0.1a
Diabetes 4 (5) 0 (0) 4 (8) 0.1a
exacerbation the previous year 48 (55) 17 (37) 31 (63) 0.01
Treated daily with bronchodilator or ICs 71 (81) 30 (75) 41 (85) 0.2
Treated daily with laBa/ICsb 47 (54) 21 (53) 26 (54) 0.9
Wheezes 22 (25) 4 (10) 18 (38) 0.003a
Crackles 11 (13) 2 (5) 9 (19) 0.06a
Diminished breath sounds 20 (23) 3 (8) 17 (35) 0.002a
Prolonged expiration 20 (23) 2 (5) 18 (38) ,0.001a
FeV1/FVC ratio ,0.7 38 (43) 7 (18) 31 (66) ,0.001
CrP $8 mg/l 12 (14) 7 (18) 5 (10) 0.3
spO2
c 95% 15 (17) 4 (10) 11 (23) 0.1a
spO2
c 92% 1 (1) 0 (0) 1 (2) 1a
Notes: aFisher’s exact test used. bCombined inhaled medication with long-acting beta2 agonist and corticosteroids. cOne missing.
Abbreviations: CrP, C-reactive protein; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; laBa/ICs, long-acting beta-agonist/inhaled corticosteroids; 
spO2, oxygen saturation.





among the COPD patients, 61.2 and 54.7. The distribution 
of change from baseline is shown in Figure 2. A significant 
drop in FEV
1
 at exacerbation (10% and at least 200 mL) was 
found in 30 patients (34%). The patients with this drop in 
lung function had more frequent COPD diagnosis at baseline 
than those without (P=0.04, Table 2). During spirometry at 
baseline 75 patients (85%) expired for more than 6 seconds, 
at exacerbation the corresponding number was 67 (76%).
Increased wheezing was the only symptom associated 
with a significant drop in lung function. Ten of the 13 patients 
who reported very bothersome wheezing had a significant 
drop in FEV
1
 (P=0.001, Table 2). In the asthma group, only 
two patients had this symptom, but a significant drop in FEV
1
 
was found in both.
An abnormal finding by chest auscultation was found in 
68 patients (77%), and a new sign (not recorded at baseline) 
was found in 48 patients (55%). Any abnormal chest sign, 
whether new or not, was recorded more frequently in patients 
with a significant drop in FEV
1
 (Table 2) compared with other 
patients. The sign “crackles” was associated with a drop in 
FEV
1
, whereas “wheezes” was not. In 26 patients (30%), one 
or more of the four chest signs were recorded both at baseline 
and exacerbation, and with similar frequency whether the 
same GP performed the auscultation at both occasions, 24% 
and 34%, respectively (P=0.3). SpO
2
 values 92% were 
found in 11 patients, and in 10 of these, the saturation had 
dropped 2% or more between baseline and exacerbation. 
This drop in SpO
2




There was a median increase in CCQ score of 1.25 for 
respiratory symptoms between baseline and exacerbation, 
but no difference was found between the patients with a 
significant drop in FEV
1
 and the other patients (Table 3).
The diagnostic value of findings, significantly indicating 
a drop in FEV
1
, is shown in Table 4. The asthma and COPD 
subgroups did not differ when it came to likelihood ratios of 
very bothersome wheezing experienced by the patients and 
crackles on auscultation. A diagnostic value of SpO
2
 dropping 
to below 93% was only found in the COPD group.
When the percentage drop in FEV
1
 was used as outcome 
in univariable linear regression, the FEV
1
/FVC ratio was 
the strongest predictor among the baseline characteristics 
(Table 5). Treatment with long-acting beta-agonist/inhaled 
corticosteroids seemed to slightly counteract the drop in 
FEV
1
, but this association was not statistically significant. 
Very bothersome wheezing during exacerbation, as experi-
enced by the patient, was the strongest indicator of change 
in FEV
1
 among the symptoms, and prolonged expiration 
and any abnormal auscultation finding were now stronger 
indicators than crackles. A decrease in SpO
2
 of at least 2% 






We have attempted to find alternatives to spirometry in 
assessing drop in lung function during asthma and COPD 
exacerbations. One strong indicator of a significant drop in 
lung function was increased wheezing as experienced by the 
patient. As far as we know, this finding has not been reported 
previously to be a sign of a drop in lung function. Patient 
experienced wheezing was a stronger predictor of drop in 
lung function than were wheezes on auscultation.
Decreased SpO
2
 measured as SpO
2
 92% was also 
strongly associated with a drop in FEV
1
. Only one COPD 
patient had SpO
2
 92% at baseline, telling us that this is a 
relevant finding for primary care. A drop in FEV
1
 was most 
Figure 1 Distribution of FeV1% predicted at baseline and during excerbation in 
88 patients diagnosed with asthma or COPD.
Abbreviation: FeV1, forced expiratory volume in 1 second.
Figure 2 Distribution of change in FeV1% predicted between baseline and 
exacerbation in 88 patients diagnosed with asthma or COPD.
Abbreviation: FeV1, forced expiratory volume in 1 second.
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Table 2 Patient characteristics, symptoms, and findings and their association with a significant drop in FEV1 at exacerbation (10% and 
at least 200 ml from baseline) in 88 patients diagnosed with asthma or COPD
Patient characteristics Significant drop in FEV1 (10% and $200 mL)
No (n=58)  
n (%)a




age $65 years 22 (42) 21 (58) 0.1
Male gender 21 (36) 13 (43) 0.97
Diagnosed with COPD or both 
asthma and COPD
27 (47) 21 (71) 0.04
exacerbation the year before 
baseline
29 (50) 16 (53) 0.8
FeV1/FVC ratio ,0.7 21 (26) 17 (57) 0.07
Treated daily with bronchodilator 
or ICs
48 (83) 23 (77) 0.5
Treated daily with laBa/ICsb 32 (55) 15 (50) 0.6
respiratory symptoms at exacerbation
shortness of breath
no or as normal 3 (5) 1 (3) 0.09c
More bothersome than normal 39 (67) 15 (50)
Very bothersome 16 (27) 14 (46)
Coughing
no or as normal 6 (10) 3 (10) 0.6c
More bothersome than normal 35 (60) 16 (53)
Very bothersome 17 (29) 11 (36)
Phlegm
no or as normal 13 (22) 9 (30) 0.7c
More bothersome than normal 37 (64) 13 (43)
Very bothersome 8 (14) 8 (27)
Wheezing
no or as normal 26 (45) 7 (23) 0.001c
More bothersome than normal 29 (50) 13 (43)
Very bothersome 3 (5) 10 (33)
Purulence
no or as normal 28 (48) 19 (63) 0.2
Increased 30 (52) 11 (37)
Chest signs at exacerbation
Wheezes 27 (47) 15 (50) 0.8
new, compared to baseline 16 (28) 9 (30) 0.8
Crackles 10 (17) 15 (50) 0.001
new, compared to baseline 8 (14) 13 (43) 0.002
Prolonged expiration 25 (43) 17 (57) 0.2
new, compared to baseline 19 (33) 10 (33) 1.0
Diminished breath sounds 10 (17) 8 (27) 0.3
new, compared to baseline 5 (9) 5 (17) 0.5
Any chest finding 34 (59) 24 (80) 0.05
new, compared to baseline 26 (45) 22 (73) 0.01
Biomarkers at exacerbation
CrP .20 mg/l (3 missing) 7 (13) 6 (21) 0.3
CrP 10 mg/l increase to $20 m/l 7 (13) 5 (17) 0.6
spO2 95% (9 missing) 14 (28) 10 (36) 0.4
spO2 2% decrease to 95% 7 (14) 9 (32) 0.05
spO2 92% 4 (8) 7 (25) 0.04
d
spO2 2% decrease to 92% 3 (6) 7 (25) 0.02
b
Notes: aSubtracting the percentage from 100 gives the specificity. bCan also be read as sensitivity. cChi-square trend. dFisher’s exact test.
Abbreviations: CrP, C-reactive protein; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; laBa/ICs, long-acting beta-agonist/inhaled corticosteroids; 
spO2, oxygen saturation.





frequently found in the patients with a COPD diagnosis, 
and the FEV
1
/FVC ratio at baseline was strongly associ-
ated with a change in lung function in the linear regression, 
indicating that the severity of the COPD should be taken 
into account.
Strengths and limitations
As part of a prospective study with baseline examinations, 
we were able to collect post-bronchodilator spirometry at 
stable state in all patients. The spirometry was well performed, 
and although fewer patients expired for more than 6 seconds 
during exacerbation than at baseline, there are reasons to 
believe that valid FEV
1
 values were obtained. The cutoff level 
of 10% for drop in FEV
1
 may be regarded as arbitrary, and the 
results are strengthened by using the percentage drop in FEV
1
 
as continuous outcome variable in linear regression.
Findings at exacerbation could also be shown as new find-
ings compared to stable state. However, we did not find any 
great benefit of taking the baseline findings into account.
One may question whether including both COPD and asthma 
patients was a good idea. One good reason for doing this is the 
difficulties in differentiating between asthma and COPD in 
many patients with obstructive lung disease.11,16 A second jus-
tification is the similar challenges in the two diseases when it 
comes to treating exacerbations with oral corticosteroids.
This is rather a small clinical study, and the results should 
be interpreted with caution. Not all patients who were assessed 
during exacerbation were included, due to incomplete data 
collection in the practices. Whereas the collection of baseline 
data was well organized, the participating practices were 
not always as prepared when it came to the exacerbations. 
Table 4 Likelihood ratio of selected findings for a significant drop 
in FeV1 at exacerbation (10% and at least 200 ml from baseline) 
in 88 patients diagnosed with asthma or COPD









∞ 3.3 (1.0–11.4) 6.4 (1.9–21.7)
Crackles, at 
exacerbation
3.4 (1.1–11.1) 2.4 (1.0–5.3) 2.9 (1.5–5.7)
Any new chest finding 
at exacerbation 
compared to baseline
1.7 (0.9–3.3) 1.5 (1.0–2.3) 1.6 (1.1–2.3)
spO2
a 2% decrease 
from baseline 
to 92%
0 5.1 (1.2–22.0) 4.3 (1.2–15.2)
Note: anine missing.
Abbreviations: FeV1, forced expiratory volume in 1 second; spO2, oxygen saturation.
Table 5 associations analyzed by linear regressiona between 
baseline characteristics and symptoms and findings at exacerbation 
and the percentage drop in FeV1 from baseline in 88 patients 





Diagnosed with COPD −5.6 0.05
history of frequent exacerbations −2.1 0.4
FeV1/FVC ratio at baseline 0.39 0.002
FeV1/FVC ratio ,0.7 at baseline −4.8 0.1
Daily treatment with laBa/ICs 3.5 0.1
symptoms at exacerbation
short of breath, very bothersome −5.2 0.04
Coughing, very bothersome −3.5 0.2
Phlegm, very bothersome −6.2 0.06
Wheezing, very bothersome −15.5 ,0.001




Prolonged expiration −5.4 0.02
Diminished breath sounds −4.7 0.8
Any chest finding −5.7 0.02
CrPb .20 mg/l (3 missing) −8.4 0.02
spO2
c 95% (9 missing) −5.2 0.08
spO2 92% (9 missing) −11.9 0.001
Notes: aadjusted for age, gender, and FeV 1% predicted at baseline. bThree missing. 
cnine missing.
Abbreviations: CrP, C-reactive protein; FeV1, forced expiratory volume in 
1 second; FVC, forced vital capacity; laBa/ICs, long-acting beta-agonist/inhaled 
corticosteroids; spO2, oxygen saturation.
Table 3 Median CCQ scores at exacerbation and change in 
median CCQ score compared with baseline, and significant 
drop in FeV1 from baseline (10% and $200 ml) in 78 patients
a 
diagnosed with asthma or COPD
Symptoms and CCQ scores A drop in FEV1 from 




shortness of breath at rest (n=78) 2 2 0.2
Change from baseline (n=77) 1 1 0.4
shortness of breath on effort (n=78) 4 4 0.9
Change from baseline (n=77) 2 1 0.09
Cough (n=78) 4 4 0.9
Change from baseline (n=78) 1 1 0.2
Phlegm (n=78) 3 3 0.6
Change from baseline 0 1 0.2
CCQ respiratory score (n=75) 3.5 3.25 0.5
Change from baseline (n=73) 1.25 1.0 0.6
CCQ total score (n=74) 2.6 2.6 0.8
Change from baseline 1.05 0.7 0.9
Notes: aIn 10 of the 88 patients in the study sample, CCQ was not filled in at 
exacerbation. bMann–Whitney test.
Abbreviations: CCQ, Clinical COPD Questionnaire; FeV1, forced expiratory 
volume in 1 second.
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This has probably not resulted in any systematic selection 
bias influencing the association between findings and drop 
in lung function.
Comparisons with existing 
literature
We have not found studies evaluating wheezing, as experi-
enced by patients, as a sign of drop in lung function, only as 
an independent predictor of COPD in general.17 Wheezing 
is not one of the items in score sheets for health status in 
COPD patients, such as the CCQ12 and the COPD assess-
ment test (CAT)18 and neither in the exacerbations of chronic 
pulmonary disease tool (EXACT).19
Decreased SpO
2
 during COPD exacerbations has been 
shown in previous studies,20,21 but decreased SpO
2
 has not 
previously been linked to the magnitude of drop in FEV
1
. 
A strong link between reduced FEV
1
 and reduced pulse 
oximetry values has been shown in several studies, also 
among asthma and COPD patients in general practice.22 Intro-
duction of pulse oximeters in primary care was recommended 
in 2010,23 and our results support this development.
In a previous publication from this project, we showed 
that decreased SpO
2
 predicted treatment with oral corti-
costeroids.24 There was, however, no association between 
patient experienced wheezing and the prescribing of oral 
corticosteroids (among the 13 patients with very bothersome 
wheezing, 6 [46.2%] were treated with oral corticosteroids, 
compared to 40% in the remaining patients).
One may question why not just spirometry can be used 
in the assessment of lung function during asthma and COPD 
exacerbations. It was successfully applied in this study and 
has also been performed in other studies without reports of 
adverse experiences.9,10 The recommendation in the GOLD 
guidelines, not to use spirometry during exacerbations,5 
is probably based on experiences from hospital and with 
severely ill outpatients. In primary care, the majority of 
COPD patients have a mild or moderate disease, as was also 
the case in this study. When a spirometry result from stable 
state is available and performed within the previous year, 
a new spirometry can usually give a valid measure of drop 
in lung function. However, coughing may force the patient 
to terminate the expiratory maneuver too early, and this may 
explain why the expiration lasted less than 6 seconds more 
frequently during exacerbation than at baseline in this study. 
Clinical assessment without spirometry is often needed.
To find wheezes by auscultation of the chest might be more 
useful in clinical practice than shown in this study. Wheezes 
were recorded as present or absent, but their intensity in terms 
of number and duration was not documented. Consequently, 
when wheezes were recorded as present in both stable state 
and during exacerbation, we had no information about the 
change in the intensity. This can also explain why compari-
son with stable state was of little help. The difficulties in 
interpreting auscultation findings also relate to crackles and 
prolonged expiration, which were stronger indicators of a 
drop in FEV
1
 than wheezes in this study.
To ask primary care patients with asthma or COPD 
exacerbations about wheezing seems to be a simple and a 
rational approach when assessing change in lung function. 
Measuring SpO
2
 with pulse oximetry is useful, particularly in 
COPD patients with severe symptoms. Increased “wheezing” 
and low pulse oximetry values are probably useful to take into 
account when treatment with oral corticosteroids is consid-
ered. However, we do not know to which degree treatment 
with oral corticosteroids should be based on a drop in FEV
1
. 
More studies are needed to help identify the clinical findings 
that can be helpful in the difficult decision to prescribe this 
potent medication.
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